{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:16:56Z","timestamp":1794629816499,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K09292"],"award-info":[{"award-number":["19K09292"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08985"],"award-info":[{"award-number":["22K08985"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K08668"],"award-info":[{"award-number":["19K08668"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08294"],"award-info":[{"award-number":["22K08294"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Malignant mesothelioma (MMe) is a rare but aggressive malignancy. Although the molecular genetics of MMe is known, including\n                    <jats:italic>BRCA1-associated protein-1<\/jats:italic>\n                    (\n                    <jats:italic>BAP1<\/jats:italic>\n                    ) gene alterations, the prognosis of MMe patients remains poor. Here, we generated BAP1 knockout (\n                    <jats:italic>BAP1<\/jats:italic>\n                    -KO) human mesothelial cell clones to develop molecular-targeted therapeutics based on genetic alterations in MMe. cDNA microarray and quantitative RT-PCR (qRT-PCR) analyses revealed high expression of a\n                    <jats:italic>calcium\/calmodulin-dependent protein kinase type II subunit delta<\/jats:italic>\n                    (\n                    <jats:italic>CAMK2D<\/jats:italic>\n                    ) gene in the\n                    <jats:italic>BAP1<\/jats:italic>\n                    -KO cells. CAMK2D was highly expressed in 70% of the human MMe tissues (56\/80) and correlated with the loss of BAP1 expression, making it a potential diagnostic and therapeutic target for\n                    <jats:italic>BAP1<\/jats:italic>\n                    -deficient MMe. We screened an anticancer drugs library using\n                    <jats:italic>BAP1<\/jats:italic>\n                    -KO cells and successfully identified a CaMKII inhibitor, KN-93, which displayed a more potent and selective antiproliferative effect against\n                    <jats:italic>BAP1<\/jats:italic>\n                    -deficient cells than cisplatin or pemetrexed. KN-93 significantly suppressed the tumor growth in mice xenografted with\n                    <jats:italic>BAP1<\/jats:italic>\n                    -deficient MMe cells. This study is the first to provide a potential molecular-targeted therapeutic approach for\n                    <jats:italic>BAP1-<\/jats:italic>\n                    deficient MMe.\n                  <\/jats:p>","DOI":"10.1038\/s41420-023-01552-5","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T13:01:52Z","timestamp":1689944512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2165-7565","authenticated-orcid":false,"given":"Sivasundaram","family":"Karnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-2921","authenticated-orcid":false,"given":"Akinobu","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Lutfur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5915-8935","authenticated-orcid":false,"given":"Md","family":"Wahiduzzaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-7557","authenticated-orcid":false,"given":"Muhammad Nazmul","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lam Quang","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Hanamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Inoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Riku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1131-4905","authenticated-orcid":false,"given":"Hiroyuki","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"1552_CR1","doi-asserted-by":"publisher","first-page":"13618","DOI":"10.1073\/pnas.1105887108","volume":"108","author":"M Carbone","year":"2011","unstructured":"Carbone M, Baris YI, Bertino P, Brass B, Comertpay S, Dogan AU, et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci USA. 2011;108:13618\u201323.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1552_CR2","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","volume":"18","author":"M Carbone","year":"2012","unstructured":"Carbone M, Yang H. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res. 2012;18:598\u2013604.","journal-title":"Clin Cancer Res"},{"key":"1552_CR3","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-18-4093","volume":"79","author":"A-M Kukuyan","year":"2019","unstructured":"Kukuyan A-M, Sementino E, Kadariya Y, Menges CW, Cheung M, Tan Y, et al. Inactivation of Bap1 cooperates with losses of Nf2 and Cdkn2a to drive the development of pleural malignant mesothelioma in conditional mouse models. Cancer Res. 2019;79:4113\u201323.","journal-title":"Cancer Res"},{"key":"1552_CR4","first-page":"402","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA: A Cancer J Clin. 2019;69:402\u201329.","journal-title":"CA: A Cancer J Clin"},{"key":"1552_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ajim.20209","volume":"48","author":"T Driscoll","year":"2005","unstructured":"Driscoll T, Nelson DI, Steenland K, Leigh J, Concha-Barrientos M, Fingerhut M, et al. The global burden of disease due to occupational carcinogens. Am J Ind Med. 2005;48:419\u201331.","journal-title":"Am J Ind Med"},{"key":"1552_CR6","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.3390\/ijerph17186900","volume":"17","author":"O Chimed-Ochir","year":"2020","unstructured":"Chimed-Ochir O, Arachi D, Driscoll T, Lin R-T, Takala J, Takahashi K. Burden of mesothelioma deaths by national income category: current status and future implications. Int J Environ Res Public Health. 2020;17:6900.","journal-title":"Int J Environ Res Public Health"},{"key":"1552_CR7","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344.","journal-title":"J Clin Oncol"},{"key":"1552_CR8","doi-asserted-by":"publisher","first-page":"e000506","DOI":"10.1136\/bmjresp-2019-000506","volume":"8","author":"S Gunatilake","year":"2021","unstructured":"Gunatilake S, Lodge D, Neville D, Jones T, Fogg C, Bassett P, et al. Predicting survival in malignant pleural mesothelioma using routine clinical and laboratory characteristics. BMJ Open Respir Res. 2021;8:e000506.","journal-title":"BMJ Open Respir Res"},{"key":"1552_CR9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","volume":"75","author":"G Guo","year":"2015","unstructured":"Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015;75:264\u20139.","journal-title":"Cancer Res"},{"key":"1552_CR10","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/cas.12698","volume":"106","author":"S Hakiri","year":"2015","unstructured":"Hakiri S, Osada H, Ishiguro F, Murakami H, Murakami-Tonami Y, Yokoi K, et al. Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells. Cancer Sci. 2015;106:990\u20139.","journal-title":"Cancer Sci"},{"key":"1552_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","volume":"6","author":"M Cheung","year":"2017","unstructured":"Cheung M, Testa JR. BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl Lung Cancer Res. 2017;6:270\u20138.","journal-title":"Transl Lung Cancer Res"},{"key":"1552_CR12","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","volume":"11","author":"M Carbone","year":"2016","unstructured":"Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, et al. Consensus report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol. 2016;11:1246\u201362.","journal-title":"J Thorac Oncol"},{"key":"1552_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.humpath.2014.10.015","volume":"46","author":"A Piris","year":"2015","unstructured":"Piris A, Mihm MC, Hoang MP. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations. Hum Pathol. 2015;46:239\u201345.","journal-title":"Hum Pathol"},{"key":"1552_CR14","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1001\/jamadermatol.2017.2330","volume":"153","author":"AM Haugh","year":"2017","unstructured":"Haugh AM, Njauw C-N, Bubley JA, Verz\u00ec AE, Zhang B, Kudalkar E, et al. Genotypic and phenotypic features of BAP1 cancer syndrome: a report of 8 new families and review of cases in the literature. JAMA Dermatol. 2017;153:999\u20131006.","journal-title":"JAMA Dermatol"},{"key":"1552_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/cas.13871","volume":"110","author":"M Wahiduzzaman","year":"2019","unstructured":"Wahiduzzaman M, Karnan S, Ota A, Hanamura I, Murakami H, Inoko A, et al. Establishment and characterization of CRISPR\/Cas9-mediated NF2\u2212\/\u2212 human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma. Cancer Sci. 2019;110:180\u201393.","journal-title":"Cancer Sci"},{"key":"1552_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41420-020-00364-1","volume":"6","author":"S Karnan","year":"2020","unstructured":"Karnan S, Ota A, Murakami H, Rahman ML, Hasan MN, Wahiduzzaman M, et al. Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma. Cell Death Discov. 2020;6:127.","journal-title":"Cell Death Discov"},{"key":"1552_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.apsb.2016.11.001","volume":"7","author":"C Cui","year":"2017","unstructured":"Cui C, Merritt R, Fu L, Pan Z. Targeting calcium signaling in cancer therapy. Acta Pharm Sin B. 2017;7:3\u201317.","journal-title":"Acta Pharm Sin B."},{"key":"1552_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-8-62","volume":"8","author":"P Nymark","year":"2007","unstructured":"Nymark P, Lindholm PM, Korpela MV, Lahti L, Ruosaari S, Kaski S, et al. Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines. BMC Genomics. 2007;8:62.","journal-title":"BMC Genomics"},{"key":"1552_CR19","first-page":"3796","volume":"16","author":"X Xu","year":"2018","unstructured":"Xu X, Zheng Z, Jia L, Suo S, Liu B, Shao T, et al. Overexpression of SMARCA2 or CAMK2D is associated with cisplatin resistance in human epithelial ovarian cancer. Oncol Lett. 2018;16:3796\u2013804.","journal-title":"Oncol Lett"},{"key":"1552_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc3459","volume":"13","author":"M Carbone","year":"2013","unstructured":"Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013;13:153\u20139.","journal-title":"Nat Rev Cancer"},{"key":"1552_CR21","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm.3947","volume":"21","author":"LM LaFave","year":"2015","unstructured":"LaFave LM, B\u00e9guelin W, Koche R, Teater M, Spitzer B, Chramiec A, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015;21:1344\u20139.","journal-title":"Nat Med"},{"key":"1552_CR22","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature22798","volume":"546","author":"A Bononi","year":"2017","unstructured":"Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, et al. BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature. 2017;546:549\u201353.","journal-title":"Nature."},{"key":"1552_CR23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.yjmcc.2019.01.001","volume":"127","author":"B Hegyi","year":"2019","unstructured":"Hegyi B, Bers DM, Bossuyt J. CaMKII signaling in heart diseases: emerging role in diabetic cardiomyopathy. J Mol Cell Cardiol. 2019;127:24611725-3459.","journal-title":"J Mol Cell Cardiol"},{"key":"1552_CR24","doi-asserted-by":"crossref","unstructured":"Wang Y-Y, Zhao R, Zhe H. The emerging role of CaMKII in cancer. Oncotarget. 2015;6:1172511725-3434.","DOI":"10.18632\/oncotarget.3955"},{"key":"1552_CR25","first-page":"1690","volume":"12","author":"C Liu","year":"2019","unstructured":"Liu C, Huang Q, Ma W, Qi L, Wang Y, Qu T, et al. A combination of tumor and molecular markers predicts a poor prognosis in lung adenocarcinoma. Int J Clin Exp Pathol. 2019;12:1690\u2013701.","journal-title":"Int J Clin Exp Pathol"},{"key":"1552_CR26","doi-asserted-by":"publisher","first-page":"E1026","DOI":"10.1073\/pnas.1217072110","volume":"110","author":"A Britschgi","year":"2013","unstructured":"Britschgi A, Bill A, Brinkhaus H, Rothwell C, Clay I, Duss S, et al. Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling. Proc Natl Acad Sci USA. 2013;110:E1026\u201334.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1552_CR27","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1158\/0008-5472.CAN-17-2392","volume":"78","author":"G Yu","year":"2018","unstructured":"Yu G, Cheng CJ, Lin SC, Lee YC, Frigo DE, Yu-Lee LY, et al. Organelle-derived acetyl-CoA promotes prostate cancer cell survival, migration, and metastasis via activation of calmodulin kinase II. Cancer Res. 2018;78:2490\u2013502.","journal-title":"Cancer Res"},{"key":"1552_CR28","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.3748\/wjg.v23.i33.6111","volume":"23","author":"W Chen","year":"2017","unstructured":"Chen W, An P, Quan XJ, Zhang J, Zhou ZY, Zou LP, et al. Ca(2+)\/calmodulin-dependent protein kinase II regulates colon cancer proliferation and migration via ERK1\/2 and p38 pathways. World J Gastroenterol. 2017;23:6111\u20138.","journal-title":"World J Gastroenterol."},{"key":"1552_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jbior.2017.12.001","volume":"68","author":"H Ando","year":"2018","unstructured":"Ando H, Kawaai K, Bonneau B, Mikoshiba K. Remodeling of Ca(2+) signaling in cancer: Regulation of inositol 1,4,5-trisphosphate receptors through oncogenes and tumor suppressors. Adv Biol Regul. 2018;68:64\u201376.","journal-title":"Adv Biol Regul"},{"key":"1552_CR30","doi-asserted-by":"crossref","unstructured":"Nassal D, Gratz D, Hund TJ. Challenges and opportunities for therapeutic targeting of calmodulin kinase II in heart. Front Pharmacol. 2020;11:35.","DOI":"10.3389\/fphar.2020.00035"},{"key":"1552_CR31","doi-asserted-by":"crossref","unstructured":"Villalobo A, Berchtold MW. The role of calmodulin in tumor cell migration, invasiveness, and metastasis. Int J Mol Sci. 2020;21:765.","DOI":"10.3390\/ijms21030765"},{"key":"1552_CR32","doi-asserted-by":"publisher","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","volume":"6","author":"IM Shapiro","year":"2014","unstructured":"Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 2014;6:237ra68.","journal-title":"Sci Transl Med"},{"key":"1552_CR33","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","volume":"10","author":"M Nasu","year":"2015","unstructured":"Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015;10:565\u201376.","journal-title":"J Thorac Oncol"},{"key":"1552_CR34","doi-asserted-by":"publisher","first-page":"13432","DOI":"10.1073\/pnas.1612074113","volume":"113","author":"Y Yoshikawa","year":"2016","unstructured":"Yoshikawa Y, Emi M, Hashimoto-Tamaoki T, Ohmuraya M, Sato A, Tsujimura T, et al. High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proc Natl Acad Sci USA. 2016;113:13432\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1552_CR35","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/carcin\/bgw084","volume":"37","author":"T Kakiuchi","year":"2016","unstructured":"Kakiuchi T, Takahara T, Kasugai Y, Arita K, Yoshida N, Karube K, et al. Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferation. Carcinogenesis. 2016;37:1098\u2013109.","journal-title":"Carcinogenesis."},{"key":"1552_CR36","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281\u2013308.","journal-title":"Nat Protoc"},{"key":"1552_CR37","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1093\/nar\/gkv1338","volume":"44","author":"S Karnan","year":"2016","unstructured":"Karnan S, Ota A, Konishi Y, Wahiduzzaman M, Hosokawa Y, Konishi H. Improved methods of AAV-mediated gene targeting for human cell lines using ribosome-skipping 2A peptide. Nucleic Acids Res. 2016;44:e54.","journal-title":"Nucleic Acids Res"},{"key":"1552_CR38","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1002\/cam4.2931","volume":"9","author":"S Kondo","year":"2020","unstructured":"Kondo S, Ota A, Ono T, Karnan S, Wahiduzzaman M, Hyodo T, et al. Discovery of novel molecular characteristics and cellular biological properties in ameloblastoma. Cancer Med. 2020;9:2904\u201317.","journal-title":"Cancer Med"},{"key":"1552_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41420-021-00446-8","volume":"7","author":"S Karnan","year":"2021","unstructured":"Karnan S, Hanamura I, Ota A, Takasugi S, Nakamura A, Takahashi M, et al. CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia. Cell Death Discov. 2021;7:121.","journal-title":"Cell Death Discov"},{"key":"1552_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.canlet.2018.06.027","volume":"433","author":"M Wahiduzzaman","year":"2018","unstructured":"Wahiduzzaman M, Ota A, Karnan S, Hanamura I, Mizuno S, Kanasugi J, et al. Novel combined Ato-C treatment synergistically suppresses proliferation of Bcr-Abl-positive leukemic cells in vitro and in vivo. Cancer Lett. 2018;433:117\u201330.","journal-title":"Cancer Lett"},{"key":"1552_CR41","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1111\/cas.13013","volume":"107","author":"T Ito","year":"2016","unstructured":"Ito T, Matsubara D, Tanaka I, Makiya K, Tanei ZI, Kumagai Y, et al. Loss of YAP1 defines neuroendocrine differentiation of lung tumors. Cancer Sci. 2016;107:1527\u201338.","journal-title":"Cancer Sci"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01552-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01552-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01552-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T13:02:16Z","timestamp":1689944536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01552-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1552"],"URL":"https:\/\/doi.org\/10.1038\/s41420-023-01552-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2323473\/v1","asserted-by":"object"}]},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"5 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"257"}}